Clinical Trial: Pyrotinib Combined With Trastuzumab and Pertuzumab for Maintenance Therapy in HER2-Positive Advanced Breast Cancer

U.S., March 14 -- ClinicalTrials.gov registry received information related to the study (NCT07470203) titled 'Pyrotinib Combined With Trastuzumab and Pertuzumab for Maintenance Therapy in HER2-Positive Advanced Breast Cancer' on March 09.

Brief Summary: This is a Prospective, Single-Arm, Observational, Real-World Study. The purpose of this study is to evaluate the safety and efficacy of pyrotinib combined with trastuzumab and pertuzumab for maintenance therapy in HER2-positive advanced breast cancer in the real-world setting.

Study Start Date: March 31

Study Type: OBSERVATIONAL

Condition: HER2-positive Breast Cancer

Intervention: DRUG: Pyrotinib

240~320mg given by mouth (orally) once daily every 21days

DRUG: Trastuzuma

6mg/kg give...